FDC Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
November 08, 2023 at 07:45 am EST
Share
FDC Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 4,863.66 million compared to INR 4,449.88 million a year ago. Revenue was INR 5,136.03 million compared to INR 4,577.17 million a year ago. Net income was INR 698.2 million compared to INR 518.39 million a year ago. Basic earnings per share from continuing operations was INR 4.22 compared to INR 3.1 a year ago.
For the six months, sales was INR 10,227.42 million compared to INR 9,396.5 million a year ago. Revenue was INR 10,793.99 million compared to INR 9,715.02 million a year ago. Net income was INR 1,797.08 million compared to INR 1,225.78 million a year ago. Basic earnings per share from continuing operations was INR 10.84 compared to INR 7.35 a year ago.
FDC Limited is an India-based company, which is principally engaged in the business of pharmaceuticals. The Company manufactures and distributes its range of generics, formulations, and active pharmaceuticals at its manufacturing plants. It also manufactures oral rehydration salts (ORS) and specialized formulations. It has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. It has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics, and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.